Available on demand: Transform Medical Affairs initiatives with fact-based solutions for improved compliance.

Zephyr Health

In today’s competitive, highly regulated environment, product success is dependent upon data and fact-based decision making. More and more, Medical Affairs teams play a pivotal role in education pre- and post-launch, and the explosion of big data in healthcare is changing how they make value-based decisions that are critical to success.

This webinar explored the challenges Medical Affairs teams have in finding a repeatable, objective and compliant solution to identify and manage their strategic programmes. With a wealth of information available, it can be difficult to sort through data and understand what is important to incorporate into research and strategy. In this session you will hear needs and use cases for having a robust data strategy when it comes to Medical Affairs success. The panelists shared best practices for making fact-based decisions that meet compliance restrictions, using powerful market insights gained from multiple data sources, to optimise strategic planning and ultimately drive product success.

The live webinar took place on Tuesday 28 June at 16.00 BST / 08.00 PST. Please click here or on the button  above/below.

Participants

Blake MorrisonBlake Morrison, Founder venn5 Bioconsulting LLC

Blake Morrison, PharmD, brings 25 years clinical and industry experience with a therapeutic area emphasis on oncology. Blake’s operational areas of expertise is focused in medical affairs roles and include preclinical and clinical drug development, thought leader relationships, medical information, communication and education and supporting patient advocacy initiatives. Blake entered the pharmaceutical industry in 1998 and has held leadership roles with several biopharmaceutical firms.

His immediate past position was at Karyopharm Therapeutics as the Vice President of Medical and Scientific Affairs. He has held similar posts at Sunesis, Onyx, Genentech, Millennium and others. Additionally, he founded and operates a specialized consulting firm, venn5 BioConsulting, providing medical affairs services and KOL relationship expertise to early, oncology-focused development companies. In these roles, Blake has been associated with several successful drug development programs, new product launches and label expansions.

Harleen ParmarHarleen Parmar, Senior Product Marketing Manager, Zephyr Health

Harleen is Senior Product Marketing Manager at Zephyr Health; the Insights-as-a-Service leader harnessing the power of global healthcare data to create precise and predictive insights. She is responsible for developing go-to-market strategies and plans and sales enablement.

Prior to joining Zephyr Health, Harleen spent over six years in Medical Affairs at multiple pharmaceutical companies, including Aptalis Pharma, Bristol-Myers Squibb and Schering-Plough. Most recently, she was an Associate Director (medical, marketing and strategy) at Giant Creative Strategy, where she managed strategic brand planning, messaging and development of promotional materials for various pharmaceutical products.

Harleen is a registered pharmacist and has an MBA in marketing and pharmaceutical management.

Seth WhitelawSeth Whitelaw, President & CEO, Whitelaw Compliance Group, LLC

Seth has more than 20 years of industry experience in the life sciences and healthcare sectors, as an attorney, compliance officer and consultant. His career has focused on food and drug law and corporate governance, as well as designing and running compliance programs within medical devices, pharmaceutical sales, and marketing and pharmaceutical R&D. He is a licensed food and drug attorney, with a doctorate in Health Law.

A former Food and Drug Law Institute (FDLI) fellow, Seth worked for the FDA’s Office of Chief Counsel. As a result, of Bard’s corporate plea in the case of U.S. v. C.R. Bard, Inc., Seth served as the company’s chief compliance officer. Seth also served as the compliance officer for GlaxoSmithKline R&D, where he helped establish an R&D risk assessment and monitoring program, as well as the compliance reporting protocol.

Paul Tunnah, pharmaphorum (moderator)

Paul Tunnah is CEO and Founder of pharmaphorum media, which facilitates productive engagement for pharma, bringing healthcare together to drive medical innovation. It combines industry-leading content and social media engagement services with the globally recognised news, information and insight portal pharmaphorum.com, working with pharmaceutical companies, service providers and broader healthcare organisations to help communicate their thought leadership and connect them with relevant stakeholders.

* When you click to register for this webinar you will be taken to a website run by BrightTalk who host the webinar and gather your registration data.
This data may then be passed to pharmaphorum media limited, and in turn passed to the company(ies) we are partnering with to bring you the webinar. This data may be used by us and them for occasional marketing purposes. It will not be shared with any further third parties.
By clicking to register for this webinar you give consent for any data you provide to be used in this way.
If at any point you no longer wish to be contacted based on the information you provide during the registration for this webinar, please send an email to info@pharmaphorum.com requesting that your information is deleted in accordance with the General Data Protection Regulation.